Meet the co-developer of the first commercial mAb and gene therapy – Labiotech.eu (blog)
Labiotech.eu (blog) |
Meet the co-developer of the first commercial mAb and gene therapy
Labiotech.eu (blog) Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene therapy, Glybera. I was curious to know what he did to … |
